2022
Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance
Stenger E, Xiang Y, Wetzel M, Gillespie S, Chellapandian D, Shah R, Arnold S, Bhatia M, Chaudhury S, Eckrich M, Kanter J, Kasow K, Krajewski J, Nickel R, Ngwube A, Olson T, Rangarajan H, Wobma H, Guilcher G, Horan J, Krishnamurti L, Shenoy S, Abraham A. Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance. Transplantation And Cellular Therapy 2022, 29: 47.e1-47.e10. PMID: 36273784, DOI: 10.1016/j.jtct.2022.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Sickle CellGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansRetrospective StudiesTransplantation, HomologousConceptsHematopoietic cell transplantationSickle cell diseaseOrgan functionMultivariable analysisBrain magnetic resonance imagingCentral nervous system indicationsPost-HCT patientsRelated bone marrowSevere acute GVHDPredictors of dysfunctionLong-term survivalMagnetic resonance imagingSevere clinical phenotypeAcute GVHDChronic graftIntense conditioningHost diseaseMyeloablative conditioningNeurologic eventsOvert strokeRetrospective cohortMedian ageOrgan dysfunctionCardiac dysfunctionCell transplantation
2021
Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease
Mupfudze T, Meyer C, Preussler J, Mau L, Bolon Y, Steinert P, Arnold S, Saber W, Krishnamurti L. Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: 685.e1-685.e8. PMID: 33895405, PMCID: PMC8680220, DOI: 10.1016/j.jtct.2021.04.009.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Sickle CellHematopoietic Stem Cell TransplantationHumansInsurance, HealthMedicaidRetrospective StudiesUnited StatesConceptsEvent-free survivalSickle cell diseaseHematopoietic cell transplantation outcomesSignificant between-group differencesGraft failureOverall survivalChronic GVHDCell transplantation outcomesBetween-group differencesAcute GVHDCumulative incidenceAlloHCT outcomesTransplantation outcomesInsurance statusCell diseaseAllogeneic hematopoietic cell transplantation outcomesLower event-free survivalPrivate insuranceRecipients of MedicaidProportion of patientsRetrospective multicenter studyKaplan-Meier methodPrivate insurance groupMarrow Transplant ResearchHealth insurance status
2020
Mortality in sickle cell disease: A population‐based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India
Sheshadri V, Shabeer P, Santhirapala V, Jayaram A, Krishnamurti L, Menon N. Mortality in sickle cell disease: A population‐based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India. Pediatric Blood & Cancer 2020, 68: e28875. PMID: 33381914, DOI: 10.1002/pbc.28875.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCause of deathCell diseaseMortality rateSeverity of SCDAge groupsAboriginal populationAcute chest syndromePopulation-based studyPercent of deathsCrude mortality rateCommunity-based comprehensive careCause of mortalityCases of deathPaucity of dataCommon monogenic disorderChest syndromeMedian ageHospital recordsSCD patientsAutopsy questionnaireAboriginal communitiesComprehensive careLongitudinal cohortRemote Aboriginal communities
2014
Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluation
Kato-Lin Y, Krishnamurti L, Padman R, Seltman H. Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluation. International Journal Of Medical Informatics 2014, 83: 814-824. PMID: 25179666, DOI: 10.1016/j.ijmedinf.2014.08.003.Peer-Reviewed Original ResearchConceptsVaso-occlusive pain crisesSickle cell diseasePain managementMixed-methods evaluationPain crisisEmergency departmentHealth information technologyCell diseaseInpatient unitSickle cell disease patientsIndividualized pain plansAnalgesic ordersPain planED visitsFirst dosePediatric patientsChildren's HospitalDisease patientsHigh baseline performanceClinicians insightNurses' perspectivesPatient recordsHealth information systemsSimple interventionCare qualityProdromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell Disease
Creary S, Krishnamurti L. Prodromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell Disease. Journal Of Pediatric Hematology/Oncology 2014, 36: 480-483. PMID: 24633302, DOI: 10.1097/mph.0000000000000146.Peer-Reviewed Original ResearchConceptsAcute chest syndromeSickle cell diseaseProdromal illnessCell diseaseChest syndromePainful vaso-occlusive crisesHistory of asthmaThird of patientsVaso-occlusive crisisICD-9-CMAcute visitsACS episodeChart reviewPediatric patientsPediatric hospitalHigh riskCommon reasonPatientsIllnessCareDiseaseVisitsSyndromeChildrenFurther research
2013
Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities
Cruz R, Ranganathan S, Mazariegos G, Soltys K, Nayyar N, Sun Q, Bond G, Shaw P, Haberman K, Krishnamurti L, Marsh J, Humar A, Sindhi R. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities. Surgery 2013, 153: 150-159. PMID: 23331862, DOI: 10.1016/j.surg.2012.11.006.Peer-Reviewed Original ResearchConceptsTumor histologyLiver transplantationNational Cancer Institute's SurveillanceFavorable tumor histologyHepatic artery thrombosisEnd Results registryUnresectable liver malignanciesDeterminants of survivalLTx centersPosttransplantation outcomesArtery thrombosisNonmalignant indicationsPulmonary metastasesSurgical resectionChildren's HospitalPatient survivalTumor lysisUnited NetworkLiver malignanciesTumor necrosisAntithrombotic agentsOrgan SharingHepatoblastoma casesLTxStage III
2011
Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial
Peters-Lawrence M, Bell M, Hsu L, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith W, Dampier C, Minniti C, Network F. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemporary Clinical Trials 2011, 33: 291-297. PMID: 22155024, PMCID: PMC3577351, DOI: 10.1016/j.cct.2011.11.018.Peer-Reviewed Original ResearchConceptsNew England Research InstituteClinical trialsRandomized clinical trialsFuture clinical trialsClinical trial implementationComplex dosing schedulesClinical Research NetworkPatient Controlled AnalgesiaProtocol acceptanceSCD clinicPain controlPain crisisAcute painDosing schedulesAcute interventionOutside physiciansUrgent careEligibility criteriaEnrollment periodPatient encountersEarly closurePainRecruitment barriersTrialsStaff availability
2006
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood & Cancer 2006, 47: 907-913. PMID: 16496290, DOI: 10.1002/pbc.20791.Peer-Reviewed Original ResearchConceptsElevated tricuspid regurgitant velocityTricuspid regurgitant velocitySickle cell diseaseAcute chest syndromePulmonary hypertensionCerebrovascular diseaseVasoocclusive crisisSCD patientsReticulocyte countCell diseaseType of SCDTricuspid regurgitant jet velocityLife-threatening complicationsObstructive sleep apneaPediatric SCD patientsRegurgitant jet velocityElevated reticulocyte countSignificant differencesNumber of echocardiogramsChest syndromeEchocardiographic evidenceOutpatient echocardiogramMean hemoglobinClinical characteristicsHydroxyurea therapy